ATE419276T2 - Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d - Google Patents

Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d Download PDF

Info

Publication number
ATE419276T2
ATE419276T2 AT01927974T AT01927974T ATE419276T2 AT E419276 T2 ATE419276 T2 AT E419276T2 AT 01927974 T AT01927974 T AT 01927974T AT 01927974 T AT01927974 T AT 01927974T AT E419276 T2 ATE419276 T2 AT E419276T2
Authority
AT
Austria
Prior art keywords
mab
monoclonal antibodies
effector cells
antibody
adcc
Prior art date
Application number
AT01927974T
Other languages
English (en)
Inventor
Roland Beliard
Dominique Bourel
Arnaud Glacet
Romeuf Christophe De
Nicolas Bihoreau
Emmanuel Nony
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8849165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419276(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Application granted granted Critical
Publication of ATE419276T2 publication Critical patent/ATE419276T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01927974T 2000-04-12 2001-04-12 Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d ATE419276T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0004685A FR2807767B1 (fr) 2000-04-12 2000-04-12 Anticorps monoclonaux anti-d

Publications (1)

Publication Number Publication Date
ATE419276T2 true ATE419276T2 (de) 2009-01-15

Family

ID=8849165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927974T ATE419276T2 (de) 2000-04-12 2001-04-12 Verfahren von antikörper mit adcc via cd16, z.b. monoklonale antikörper gegen rhesus d

Country Status (11)

Country Link
US (13) US7579170B2 (de)
EP (4) EP2947099A1 (de)
JP (9) JP5192625B2 (de)
AT (1) ATE419276T2 (de)
AU (3) AU2001254858B2 (de)
CA (1) CA2406033C (de)
DE (1) DE60137210D1 (de)
DK (3) DK1518864T4 (de)
ES (3) ES2601241T3 (de)
FR (1) FR2807767B1 (de)
WO (1) WO2001077181A2 (de)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (de) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
ATE503829T1 (de) * 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1537419B1 (de) * 2002-09-13 2011-06-01 LFB Biotechnologies Test für CD16-vermittelte ADCC Effektivität von monoklonalen oder polklonalen Antikörpern
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844521B1 (fr) * 2002-09-13 2004-12-24 Lab Francais Du Fractionnement Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices
FR2844520B1 (fr) * 2002-09-13 2006-06-09 Lab Francais Du Fractionnement Utilisation d'un anticorps induisant la secretion de cytokines en therapie
EP1613654A2 (de) * 2003-04-03 2006-01-11 Laboratoire Français du Fractionnement et des Biotechnologies Antikörper mit erhöhter fähigkeit zell-funktionen zu modulieren
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
FR2861079B1 (fr) * 2003-10-20 2007-09-28 Lab Francais Du Fractionnement Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
EP1720570A4 (de) * 2004-01-26 2008-09-03 Cangene Corp Behandlung von hämorrhagischem dengue-fieber
EP2458619B1 (de) 2004-05-24 2017-08-02 Ibis Biosciences, Inc. Massenspektrometrie mit selektivem Ionfilter durch digitale Schwelle
EP1941275B1 (de) * 2005-09-29 2013-07-24 Medimmune, Inc. Verfahren zur identifizierung membran-lg-spezifischer antikörper und verwendung davon zur ansteuerung immunglobulin produzierender vorläuferzellen
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
ATE536373T1 (de) * 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
ES2396569T3 (es) * 2006-01-17 2013-02-22 Medarex, Inc. Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo y xilosilo
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
EP1933137A1 (de) * 2006-12-15 2008-06-18 Glycode Verfahren zur Untersuchung der Reaktion auf eine Behandlung mit einem monoklonalen Antikörper
US20100167315A1 (en) * 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
EP1918304A1 (de) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoklonale Antikörper gegen den humanen anti-Müller-Hormon Typ II Rezeptor (AMHR-II)
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
KR20110047258A (ko) * 2008-08-26 2011-05-06 심포젠 에이/에스 저혈소판증의 치료 방법
ES2692173T3 (es) 2008-12-31 2018-11-30 Bharat Serums And Vaccines Ltd. Anticuerpos monoclonales anti-RHD
EP2400984A4 (de) * 2009-02-25 2013-01-23 Merck Sharp & Dohme Her2-antikörperzusammensetzungen
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2233500A1 (de) 2009-03-20 2010-09-29 LFB Biotechnologies Optimierte Fc Varianten
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
KR20120054069A (ko) 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
PL3498730T3 (pl) 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2563391B1 (de) 2010-04-27 2020-08-26 Roche Glycart AG Kombinationstherapie eines afucosylierten CD20-Antikörpers mit einem mTOR-Inhibitor
CA2799595C (en) 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
JP2013535198A (ja) 2010-07-30 2013-09-12 グリコド 哺乳類のグリコシル化経路を有する酵母人工染色体
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX2013006739A (es) 2010-12-16 2013-07-17 Roche Glycart Ag Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
US9328170B2 (en) 2011-05-25 2016-05-03 Merck Sharp & Dohme Corp. Method for preparing Fc containing polypeptides having improved properties
FR2976811A1 (fr) 2011-06-22 2012-12-28 Lfb Biotechnologies Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
CN103827134A (zh) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
KR101684750B1 (ko) 2011-09-23 2016-12-08 로슈 글리카트 아게 이중특이적 항-egfr/항-igf-1r 항체
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
FR2981946B1 (fr) 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
SG11201503393SA (en) 2012-11-02 2015-06-29 Tg Therapeutics Inc Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
EP3514175A1 (de) 2012-12-17 2019-07-24 Laboratoire Français du Fractionnement et des Biotechnologies Einsatz von monoklonalen antikörpern für die behandlung von bakteriellen entzündungen und infektionen
FR3003172B1 (fr) * 2013-03-15 2017-12-08 Lab Francais Du Fractionnement Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP3594231A1 (de) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies In hohem masse galactosylierte anti-tnf-alpha-antikörper und verwendungen davon
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
KR102216003B1 (ko) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
KR102366644B1 (ko) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체 (egfr) 항체
CA2956072A1 (en) * 2014-07-21 2016-01-28 Bloodworks Antibodies that recognize red blood cell antigens
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
EP3223848B1 (de) 2014-11-27 2024-11-27 Zymeworks BC Inc. Verfahren zur verwendung von gegen her2 gerichteten bispezifischen antigenbindenden konstrukten
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
EP3091033A1 (de) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3-antikörper und verwendungen davon
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3108897A1 (de) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antikörper gegen menschliches csf-1r für die induzierung von lymphozytose in lymphomen oder leukämien
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
EP3257866A1 (de) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modifizierter anti-tnf-antikörper und verwendung davon bei der behandlung von entzündlicher darmerkrankung
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
FR3053688A1 (fr) 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN110191720A (zh) 2016-09-09 2019-08-30 Tg治疗有限公司 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
KR20240005247A (ko) 2016-10-28 2024-01-11 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
FR3064007A1 (fr) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
EP3710589A4 (de) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
EP3498293A1 (de) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
ES2958933T3 (es) 2018-03-13 2024-02-16 Zymeworks Bc Inc Conjugados de anticuerpo biparatópico anti-HER2-fármaco y métodos de uso
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP7342701B2 (ja) 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL237868B1 (pl) 2018-04-04 2021-06-14 Gdanski Univ Medyczny Mutanty punktowe czynnika B oraz białka C2 do zastosowania do wzmacniania aktywności cytotoksycznej przeciwciał w leczeniu chorób nowotworowych
EP3835321A4 (de) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha Anti-cd137-antigen-bindendes molekül und verwendung davon
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
EP3626265A1 (de) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-cd45rc-antikörper und verwendungen davon
EP3873519A1 (de) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antikörperformulierung
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
MX2021013441A (es) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd Molecula de union a antigenos, composicion farmaceutica y metodo.
CN110320352A (zh) * 2019-07-25 2019-10-11 上海轩锋生物科技有限公司 基于抗体依赖的细胞介导细胞毒性的抗体效价检测方法
US20230078601A1 (en) 2020-01-31 2023-03-16 The Cleveland Clinic Foundation Anti-mullerian hormone receptor 2 antibodies and methods of use
BR112022018161A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
KR20220152318A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
US20230139178A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
AU2022294106A1 (en) 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2022270523A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008459A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4578457A1 (de) 2022-08-24 2025-07-02 Toray Industries, Inc. Arzneimittel zur behandlung und/oder prävention von krebs
WO2024048542A1 (ja) 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び／又は予防のための医薬品
EP4582100A1 (de) 2022-08-30 2025-07-09 Toray Industries, Inc. Medikament zur behandlung und/oder prävention von krebs
CN120302998A (zh) 2022-12-23 2025-07-11 东丽株式会社 用于癌的治疗和/或预防的药品
IL322203A (en) 2023-02-17 2025-09-01 Apogee Therapeutics Inc Antibodies that bind interleukin 4 receptor alpha and methods of use
AU2024246833A1 (en) 2023-03-31 2025-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
AU2024339683A1 (en) 2023-09-13 2026-03-26 Toray Industries, Inc. Pharmaceutical composition for treating, preventing and/or diagnosing cancer
WO2025137523A2 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025137410A1 (en) 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
WO2025255353A1 (en) 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody
WO2025264960A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind ox40l
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026080829A1 (en) 2024-10-10 2026-04-16 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 13

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA406033A (en) 1942-07-14 American Can Company Product packing apparatus
GB1382265A (en) 1971-12-03 1975-01-29 Ml Aviation Co Ltd Transporters
JPS56101171A (en) 1980-01-16 1981-08-13 Fuji Xerox Co Ltd Separation failure detector for transfer paper
EP0043718B1 (de) 1980-07-07 1984-11-28 National Research Development Corporation Zellinien
WO1985002413A1 (en) 1983-11-28 1985-06-06 The Board Of Trustees Of The Leland Stanford Jr. U HUMAN MONOCLONAL ANTIBODY AGAINST Rh(D) ANTIGEN AND ITS USES
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8610106D0 (en) 1986-04-25 1986-05-29 Central Blood Lab Authority Human igm-producing heterohybridoma
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
JPS6350710A (ja) 1986-08-21 1988-03-03 Koputeitsuku:Kk 光測定装置
GB8722018D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722019D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
GB8722020D0 (en) 1987-09-18 1987-10-28 Central Blood Lab Authority Human anti-rh(d)monoclonal antibodies
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
DK0493446T3 (da) 1989-09-15 1997-08-11 Tanox Biosystems Inc Behandling af autoimmunsygdom.
FR2653561A1 (fr) * 1989-10-19 1991-04-26 Fondation Nale Transfusion San Hetero-anticorps anti-rhd et composition pharmaceutique les contenant.
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
US5773218A (en) 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
CA2116246A1 (en) 1992-06-26 1994-01-06 Roland Beliard Human monoclonal anti-rhesus (d) antibodies and cell lines producing same
JP3565572B2 (ja) * 1992-09-07 2004-09-15 協和醗酵工業株式会社 ヒト化抗体
CA2105618C (en) 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
KR100304333B1 (ko) 1993-08-24 2001-11-30 안도 고끼 재조합의사람화된항-사람면역결핍바이러스항체
FR2724182B1 (fr) 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
RU2094462C1 (ru) 1995-11-14 1997-10-27 Оловникова Наталья Ивановна Моноклональный иммуноглобулин человека класса iggi против антигена d системы резус
WO1997030173A1 (en) * 1996-02-15 1997-08-21 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel
JPH10212247A (ja) * 1996-05-31 1998-08-11 Sankyo Co Ltd 自己免疫疾患治療剤
HUP9903292A3 (en) 1996-05-31 2000-08-28 Sankyo Co Use of substances improving insulin resistance for production of remedies for autoimmune diseases
AU722127B2 (en) 1996-06-24 2000-07-20 Zlb Behring Ag Polypeptides capable of forming antigen binding structures with specificity for the rhesus D antigens, the DNA encoding them and the process for their preparation and use
JPH1080276A (ja) * 1996-07-19 1998-03-31 Mitsui Petrochem Ind Ltd バイセクト糖鎖調節法
JPH10112531A (ja) 1996-08-13 1998-04-28 Hitachi Ltd 半導体集積回路装置の製造方法
JP4550947B2 (ja) * 1997-03-19 2010-09-22 協和発酵キリン株式会社 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体
US6682928B2 (en) * 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2000005908A (ja) 1998-06-18 2000-01-11 Sony Corp 保持具、加工装置および加工方法
EP1176195B1 (de) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
ATE478150T1 (de) 1999-10-26 2010-09-15 Stichting Dienst Landbouwkundi Säugetierartige glykosylierung in pflanzen
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
EA200401325A1 (ru) * 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP1666501A4 (de) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zuckerkettenmodifizierter anti-hm1.24-antikörper
US7150443B2 (en) 2005-01-18 2006-12-19 Mills Douglas W Control valve for nitrous oxide injection system
WO2007028106A2 (en) * 2005-08-31 2007-03-08 Centocor, Inc. Host cell lines for production of antibody constant region with enhanced effector function
EP2245734B1 (de) 2008-02-18 2014-07-02 Freescale Semiconductor, Inc. Mischerschaltung

Also Published As

Publication number Publication date
JP2003534781A (ja) 2003-11-25
EP1272527B2 (de) 2018-08-29
US8153124B2 (en) 2012-04-10
US20030175969A1 (en) 2003-09-18
DK1272527T3 (da) 2009-05-04
EP2947099A1 (de) 2015-11-25
WO2001077181A2 (fr) 2001-10-18
JP2012193184A (ja) 2012-10-11
US7541029B2 (en) 2009-06-02
EP1518864B2 (de) 2019-10-16
JP2017214427A (ja) 2017-12-07
US20140162356A1 (en) 2014-06-12
JP5192625B2 (ja) 2013-05-08
JP2017012199A (ja) 2017-01-19
US7579170B2 (en) 2009-08-25
US20070009522A1 (en) 2007-01-11
WO2001077181A3 (fr) 2002-03-07
CA2406033C (fr) 2014-05-27
EP1272527B1 (de) 2008-12-31
US20180002442A1 (en) 2018-01-04
US8409572B2 (en) 2013-04-02
JP2015211696A (ja) 2015-11-26
DK1518864T3 (da) 2015-01-12
CA2406033A1 (fr) 2001-10-18
EP2341078B1 (de) 2016-08-10
AU2007202060B2 (en) 2010-10-14
DK1518864T4 (da) 2020-01-27
EP2341078A2 (de) 2011-07-06
JP2015221827A (ja) 2015-12-10
US8357370B2 (en) 2013-01-22
FR2807767B1 (fr) 2005-01-14
US20150266972A1 (en) 2015-09-24
DE60137210D1 (de) 2009-02-12
JP5722278B2 (ja) 2015-05-20
ES2601241T3 (es) 2017-02-14
US20110052571A1 (en) 2011-03-03
AU5485801A (en) 2001-10-23
US9708409B2 (en) 2017-07-18
JP2012193185A (ja) 2012-10-11
AU2001254858B2 (en) 2001-10-23
AU2010257417A1 (en) 2011-01-20
US20120259095A1 (en) 2012-10-11
AU2007202060A1 (en) 2007-05-31
DK2341078T3 (en) 2016-11-28
JP5722279B2 (ja) 2015-05-20
JP5788432B2 (ja) 2015-09-30
US8685725B2 (en) 2014-04-01
US20050249722A1 (en) 2005-11-10
US20110223658A1 (en) 2011-09-15
US20110059072A1 (en) 2011-03-10
FR2807767A1 (fr) 2001-10-19
US8124078B2 (en) 2012-02-28
JP5837859B2 (ja) 2015-12-24
ES2525762T5 (es) 2020-06-26
EP1518864A2 (de) 2005-03-30
US10081683B2 (en) 2018-09-25
JP6124958B2 (ja) 2017-05-10
US20110059073A1 (en) 2011-03-10
EP1272527A2 (de) 2003-01-08
JP2012191938A (ja) 2012-10-11
US9718889B2 (en) 2017-08-01
US8178093B2 (en) 2012-05-15
AU2010257417B2 (en) 2012-04-05
US20150152189A1 (en) 2015-06-04
EP2341078A3 (de) 2011-12-21
US9718890B2 (en) 2017-08-01
ES2320412T3 (es) 2009-05-22
JP2013155198A (ja) 2013-08-15
DK1272527T4 (da) 2019-01-02
US20120258096A1 (en) 2012-10-11
ES2525762T3 (es) 2014-12-30
US7931895B2 (en) 2011-04-26
EP1518864A3 (de) 2009-07-22
EP1518864B1 (de) 2014-10-08
ES2320412T5 (es) 2019-02-13

Similar Documents

Publication Publication Date Title
ES2525762T3 (es) Composición de anticuerpos con alta ADCC
CN107532188B (zh) Cd20结合分子及其用途
WO2004058797A3 (en) Human monoclonal antibodies against interleukin 8 (il-8)
KR20200139189A (ko) 다가 항체
WO2004045512A3 (en) Human monoclonal antibodies against cd25
WO2002100348A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
IL268593B1 (en) Polypeptides and antibodies with increased CDC activity and/or increased agonist activity and their uses in medicine
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
CA2380783A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
IL160358A0 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004035607A3 (en) Human monoclonal antibodies against cd20
JP2010522701A (ja) 二重特異性抗体およびその作製方法
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
MY142290A (en) Anti-il-6 antibodies compositions, methods and uses
Moroney et al. Modern antibody technology: the impact on drug development
DK0493446T3 (da) Behandling af autoimmunsygdom.
KR20210111767A (ko) 절단된 다가 다량체
Leibiger et al. Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma
EP0155172A3 (de) Monoklonale Antikörper gegen menschlichen Lungenkrebs
Björklund et al. Characterisation of recombinant human IgE-Fc fragments expressed in baculovirus-infected insect cells
AU2004283925A1 (en) Use of metallic cations to improve functional activity of antibodies
EA050487B1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
NZ729160B2 (en) Anti-lag3 antibodies and antigen-binding fragments

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272527

Country of ref document: EP